Suppr超能文献

氨甲环酸治疗慢性硬脑膜下血肿的非手术治疗。

Nonsurgical treatment of chronic subdural hematoma with tranexamic acid.

机构信息

Department of Neurosurgery, Kuki General Hospital, Kuki, Saitama, Japan.

出版信息

J Neurosurg. 2013 Aug;119(2):332-7. doi: 10.3171/2013.3.JNS122162. Epub 2013 May 3.

Abstract

OBJECT

Chronic subdural hematoma (CSDH) is a common condition after head trauma. It can often be successfully treated surgically by inserting a bur hole and draining the liquefied hematoma. However, to the best of the authors' knowledge, for nonemergency cases not requiring surgery, no reports have indicated the best approach for preventing hematoma enlargement or resolving it completely. The authors hypothesized that hyperfibrinolysis plays a major role in liquefaction of the hematoma. Therefore, they evaluated the ability of an antifibrinolytic drug, tranexamic acid, to completely resolve CSDH compared with bur hole surgery alone.

METHODS

From 2007 to 2011, a total of 21 patients with CSDH seen consecutively at Kuki General Hospital, Japan, were given 750 mg of tranexamic acid orally every day. Patients were identified by a retrospective records review, which collected data on the volume of the hematoma (based on radiographic measurements) and any complications. Follow-up for each patient consisted of CT or MRI every 21 days from diagnosis to resolution of the CSDH.

RESULTS

Of the 21 patients, 3 with early stages of CSDH were treated by bur hole surgery before receiving medical therapy. The median duration of clinical and radiographic follow-up was 58 days (range 28-137 days). Before tranexamic acid therapy was initiated, the median hematoma volume for the 21 patients was 58.5 ml (range 7.5-223.2 ml); for the 18 patients who had not undergone surgery, the median hematoma volume was 55.6 ml (range 7.5-140.5 ml). After therapy, the median volume for all 21 patients was 3.7 ml (range 0-22.1 ml). No hematomas recurred or progressed.

CONCLUSIONS

Chronic subdural hematoma can be treated with tranexamic acid without concomitant surgery. Tranexamic acid might simultaneously inhibit the fibrinolytic and inflammatory (kinin-kallikrein) systems, which might consequently resolve CSDH. This medical therapy could prevent the early stages of CSDH that can occur after head trauma and the recurrence of CSDH after surgery.

摘要

目的

慢性硬脑膜下血肿(CSDH)是颅脑外伤后的一种常见病症。通常通过插入一个颅骨钻孔并引流液化血肿来进行成功的手术治疗。然而,据作者所知,对于不需要手术的非紧急情况,尚无报告表明哪种方法最适合预防血肿增大或完全解决血肿问题。作者假设纤溶亢进在血肿液化中起主要作用。因此,他们评估了抗纤维蛋白溶解药物氨甲环酸与单纯颅骨钻孔手术相比,完全解决 CSDH 的能力。

方法

2007 年至 2011 年,日本菊池综合医院连续收治了 21 例 CSDH 患者,每天口服 750mg 氨甲环酸。通过回顾性病历回顾识别患者,收集血肿量(基于影像学测量)和任何并发症的数据。每位患者的随访包括从诊断到 CSDH 消退的每 21 天进行 CT 或 MRI 检查。

结果

21 例患者中,3 例早期 CSDH 在接受药物治疗前接受了颅骨钻孔手术治疗。临床和影像学随访的中位时间为 58 天(范围 28-137 天)。在开始氨甲环酸治疗之前,21 例患者的中位血肿量为 58.5ml(范围 7.5-223.2ml);未接受手术的 18 例患者的中位血肿量为 55.6ml(范围 7.5-140.5ml)。治疗后,21 例患者的中位血肿量为 3.7ml(范围 0-22.1ml)。没有血肿复发或进展。

结论

慢性硬脑膜下血肿可以用氨甲环酸治疗而无需同时手术。氨甲环酸可能同时抑制纤维蛋白溶解和炎症(激肽-激肽释放酶)系统,从而解决 CSDH。这种药物治疗可以预防颅脑外伤后早期发生的 CSDH 和手术后 CSDH 的复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验